FibroBiologics CEO Issues Letter to Shareholders
FibroBiologics, Inc., a clinical-stage biotechnology company, announced the initiation of its clinical trial for CYWC628, an investigational fibroblast-based therapy aimed at treating diabetic foot ulcers (DFUs). The company highlighted the importance of this milestone as it transitions from development to clinical execution. It plans to begin pati…